{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:05:15Z","timestamp":1791446715524,"version":"4.3.3"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jchf.2018.06.011","type":"journal-article","created":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T16:01:34Z","timestamp":1541606494000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":153,"title":["Initiation, Continuation, Switching, and Withdrawal\u00a0of Heart Failure Medical Therapies During\u00a0Hospitalization"],"prefix":"10.1016","volume":"7","author":[{"given":"Aditi A.","family":"Bhagat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2018.06.011_bib1","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.jacc.2013.05.020","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2018.06.011_bib2","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.amjcard.2011.02.322","article-title":"Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from Get with the Guidelines-Heart Failure)","volume":"107","author":"Krantz","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2018.06.011_bib3","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.jacc.2003.12.040","article-title":"Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial","volume":"43","author":"Gattis","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2018.06.011_bib4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cardfail.2007.12.008","article-title":"Inpatient initiation of \u03b2-blockade plus nurse management in vulnerable heart failure patients: a randomized study","volume":"14","author":"Krantz","year":"2008","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2018.06.011_bib5","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jacc.2008.09.031","article-title":"Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry","volume":"53","author":"Hernandez","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2018.06.011_bib6","doi-asserted-by":"crossref","first-page":"82.e1","DOI":"10.1016\/j.ahj.2006.10.008","article-title":"Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)","volume":"153","author":"Fonarow","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2018.06.011_bib7","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jacc.2008.03.048","article-title":"Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program","volume":"52","author":"Fonarow","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2018.06.011_bib8","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1161\/hc1002.105180","article-title":"Tolerability of beta-blocker initiation and titration in the Metoprolol CR\/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"105","author":"Gottlieb","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2018.06.011_bib9","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1001\/jama.289.6.712","article-title":"Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study","volume":"289","author":"Krum","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2018.06.011_bib10","article-title":"Initiation, continuation, or withdrawal of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers and outcomes in patients hospitalized with heart failure with reduced ejection fraction","volume":"6","author":"Gilstrap","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jchf.2018.06.011_bib11","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.amjmed.2016.05.008","article-title":"Renin-angiotensin system inhibition and lower 30-day all-cause readmission in Medicare beneficiaries with heart failure","volume":"129","author":"Sanam","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.jchf.2018.06.011_bib12","first-page":"A19094","volume":"132","author":"Siddiqui","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2018.06.011_bib13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jacc.2005.04.038","article-title":"Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure","volume":"46","author":"Pitt","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2018.06.011_bib14","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s11936-015-0402-1","article-title":"Mineralocorticoid receptor antagonism in acute heart failure","volume":"17","author":"Brown","year":"2015","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.jchf.2018.06.011_bib15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejim.2013.08.711","article-title":"Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure","volume":"25","author":"Ferreira","year":"2014","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jchf.2018.06.011_bib16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.cardfail.2006.11.015","article-title":"Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure","volume":"13","author":"Gao","year":"2007","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2018.06.011_bib17","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1001\/jamacardio.2017.2198","article-title":"Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial","volume":"2","author":"Butler","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2018.06.011_bib18","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.amjcard.2014.05.062","article-title":"Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study)","volume":"114","author":"Maisel","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2018.06.011_bib19","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.ahj.2010.08.036","article-title":"Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure","volume":"160","author":"Hamaguchi","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2018.06.011_bib20","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ijcard.2016.11.006","article-title":"Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone","volume":"227","author":"Lam","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2018.06.011_bib21","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1001\/jama.2012.14795","article-title":"Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction","volume":"308","author":"Hernandez","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2018.06.011_bib22","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.ahj.2013.03.007","article-title":"Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure","volume":"165","author":"Curtis","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2018.06.011_bib23","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.109.934471","article-title":"Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF)","volume":"122","author":"Fonarow","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2018.06.011_bib24","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.jacc.2006.03.030","article-title":"Beta-blocker use and outcomes among hospitalized heart failure patients","volume":"47","author":"Butler","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2018.06.011_bib25","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.cardfail.2007.06.727","article-title":"Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF","volume":"13","author":"Fonarow","year":"2007","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2018.06.011_bib26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000457946","article-title":"Discontinuation\/dose reduction of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers during acute decompensated heart failure in African-American patients with reduced left-ventricular ejection fraction","volume":"137","author":"Kane","year":"2017","journal-title":"Cardiology"},{"key":"10.1016\/j.jchf.2018.06.011_bib27","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2018.06.011_bib28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jacc.2016.04.047","article-title":"Influence of sacubitril\/valsartan (LCZ696) on 30-Day readmission after heart failure hospitalization","volume":"68","author":"Desai","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2018.06.011_bib29","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.jacc.2015.08.878","article-title":"Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF","volume":"66","author":"Simpson","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2018.06.011_bib30","first-page":"305","article-title":"Early adoption of sacubitril\/valsartan for patients with heart failure with reduced ejection fraction: insights from Get With the Guidelines\u2013Heart Failure (GWTG-HF)","volume":"5","author":"Luo","year":"2017","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2018.06.011_bib31","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1001\/jamacardio.2016.1724","article-title":"Potential mortality reduction with optimal implementation of angiotensin receptor neprilysin inhibitor therapy in heart failure","volume":"1","author":"Fonarow","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2018.06.011_bib32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ahj.2018.01.004","article-title":"Rationale and design of the comParIson Of sacubitril\/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial","volume":"198","author":"Velazquez","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2018.06.011_bib33","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jacc.2008.10.041","article-title":"Acute heart failure syndromes","volume":"53","author":"Gheorghiade","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2018.06.011_bib34","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1161\/CIRCHEARTFAILURE.115.002271","article-title":"Contemporary drug development in heart failure: call for hemodynamically neutral therapies","volume":"8","author":"Vaduganathan","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2018.06.011_bib35","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.amjcard.2008.07.045","article-title":"Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure)","volume":"102","author":"Fonarow","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2018.06.011_bib36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1161\/CIRCULATIONAHA.111.028282","volume":"125","author":"Rossignol","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2018.06.011_bib37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jacc.2017.11.025","volume":"71","author":"Yancy","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2018.06.011_bib38","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/ejhf.925","article-title":"Clinical trials in acute heart failure: beginning of the end or end of the beginning?","volume":"19","author":"Ambrosy","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2018.06.011_bib39","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2018.06.011_bib40","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ejhf.548","article-title":"Initiating sacubitril\/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens","volume":"18","author":"Senni","year":"2016","journal-title":"Eur Heart J Fail"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177918304670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177918304670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:51:01Z","timestamp":1761972661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177918304670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S2213177918304670"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2018.06.011","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initiation, Continuation, Switching, and Withdrawal\u00a0of Heart Failure Medical Therapies During\u00a0Hospitalization","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2018.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}